LEMAITRE VASCULAR INC (LMAT) Stock Fundamental Analysis
USA - NASDAQ:LMAT - US5255582018 - Common Stock
88.55 USD
-0.32 (-0.36%)
88.55 USD
0 (0%)
Taking everything into account, LMAT scores 7 out of 10 in our fundamental rating. LMAT was compared to 189 industry peers in the Health Care Equipment & Supplies industry. LMAT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. LMAT is not valued too expensively and it also shows a decent growth rate. With these ratings, LMAT could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year LMAT was profitable.
LMAT had a positive operating cash flow in the past year.
In the past 5 years LMAT has always been profitable.
In the past 5 years LMAT always reported a positive cash flow from operatings.
1.2 Ratios
LMAT has a better Return On Assets (8.16%) than 92.06% of its industry peers.
LMAT has a Return On Equity of 12.99%. This is amongst the best in the industry. LMAT outperforms 89.42% of its industry peers.
LMAT has a better Return On Invested Capital (7.70%) than 84.66% of its industry peers.
LMAT had an Average Return On Invested Capital over the past 3 years of 8.26%. This is in line with the industry average of 9.01%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.16% | ||
| ROE | 12.99% | ||
| ROIC | 7.7% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
1.3 Margins
LMAT has a better Profit Margin (20.08%) than 93.65% of its industry peers.
In the last couple of years the Profit Margin of LMAT has grown nicely.
Looking at the Operating Margin, with a value of 23.34%, LMAT belongs to the top of the industry, outperforming 93.65% of the companies in the same industry.
LMAT's Operating Margin has improved in the last couple of years.
LMAT's Gross Margin of 69.11% is fine compared to the rest of the industry. LMAT outperforms 77.25% of its industry peers.
In the last couple of years the Gross Margin of LMAT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.34% | ||
| PM (TTM) | 20.08% | ||
| GM | 69.11% |
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
2. Health
2.1 Basic Checks
LMAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
LMAT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LMAT has been increased compared to 5 years ago.
Compared to 1 year ago, LMAT has a worse debt to assets ratio.
2.2 Solvency
LMAT has an Altman-Z score of 7.54. This indicates that LMAT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.54, LMAT belongs to the best of the industry, outperforming 86.77% of the companies in the same industry.
The Debt to FCF ratio of LMAT is 3.21, which is a good value as it means it would take LMAT, 3.21 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.21, LMAT belongs to the top of the industry, outperforming 86.24% of the companies in the same industry.
A Debt/Equity ratio of 0.46 indicates that LMAT is not too dependend on debt financing.
LMAT has a Debt to Equity ratio (0.46) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 3.21 | ||
| Altman-Z | 7.54 |
ROIC/WACC0.9
WACC8.52%
2.3 Liquidity
LMAT has a Current Ratio of 13.96. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
LMAT's Current ratio of 13.96 is amongst the best of the industry. LMAT outperforms 98.41% of its industry peers.
LMAT has a Quick Ratio of 11.74. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
LMAT's Quick ratio of 11.74 is amongst the best of the industry. LMAT outperforms 95.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.96 | ||
| Quick Ratio | 11.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 23.35% over the past year.
LMAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 17.13% yearly.
LMAT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.11%.
The Revenue has been growing by 13.41% on average over the past years. This is quite good.
EPS 1Y (TTM)23.35%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%15.38%
Revenue 1Y (TTM)14.11%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%15.01%
3.2 Future
Based on estimates for the next years, LMAT will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.76% on average per year.
The Revenue is expected to grow by 9.67% on average over the next years. This is quite good.
EPS Next Y19.93%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
EPS Next 5Y9.76%
Revenue Next Year13.86%
Revenue Next 2Y11.2%
Revenue Next 3Y10.46%
Revenue Next 5Y9.67%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 42.99, LMAT can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of LMAT indicates a somewhat cheap valuation: LMAT is cheaper than 68.78% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.19, LMAT is valued quite expensively.
LMAT is valuated quite expensively with a Price/Forward Earnings ratio of 34.94.
Based on the Price/Forward Earnings ratio, LMAT is valued a bit cheaper than the industry average as 71.96% of the companies are valued more expensively.
LMAT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.50.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.99 | ||
| Fwd PE | 34.94 |
4.2 Price Multiples
LMAT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 74.07% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of LMAT indicates a somewhat cheap valuation: LMAT is cheaper than 77.78% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.32 | ||
| EV/EBITDA | 24.06 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LMAT does not grow enough to justify the current Price/Earnings ratio.
LMAT has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as LMAT's earnings are expected to grow with 12.64% in the coming years.
PEG (NY)2.16
PEG (5Y)2.51
EPS Next 2Y14.3%
EPS Next 3Y12.64%
5. Dividend
5.1 Amount
With a yearly dividend of 0.90%, LMAT is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.79, LMAT pays a better dividend. On top of this LMAT pays more dividend than 92.06% of the companies listed in the same industry.
With a Dividend Yield of 0.90, LMAT pays less dividend than the S&P500 average, which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.9% |
5.2 History
The dividend of LMAT is nicely growing with an annual growth rate of 13.60%!
LMAT has paid a dividend for at least 10 years, which is a reliable track record.
LMAT has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
34.45% of the earnings are spent on dividend by LMAT. This is a low number and sustainable payout ratio.
LMAT's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP34.45%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
88.55
-0.32 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.25%
Inst Owner Change-1.12%
Ins Owners7.8%
Ins Owner Change-9.35%
Market Cap2.00B
Revenue(TTM)234.64M
Net Income(TTM)47.12M
Analysts78.82
Price Target106.87 (20.69%)
Short Float %5.87%
Short Ratio7.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.9% |
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP34.45%
Div Incr Years13
Div Non Decr Years13
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.86%
Min EPS beat(2)-5.52%
Max EPS beat(2)3.81%
EPS beat(4)2
Avg EPS beat(4)1.56%
Min EPS beat(4)-5.52%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.62%
EPS beat(12)8
Avg EPS beat(12)3.08%
EPS beat(16)8
Avg EPS beat(16)-1.76%
Revenue beat(2)2
Avg Revenue beat(2)1.31%
Min Revenue beat(2)0.79%
Max Revenue beat(2)1.83%
Revenue beat(4)3
Avg Revenue beat(4)0.17%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.31%
Revenue beat(12)6
Avg Revenue beat(12)-0.07%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)0%
PT rev (3m)0.27%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)5.23%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)5.92%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)2.07%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)2.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.99 | ||
| Fwd PE | 34.94 | ||
| P/S | 8.54 | ||
| P/FCF | 38.32 | ||
| P/OCF | 34.12 | ||
| P/B | 5.53 | ||
| P/tB | 7.61 | ||
| EV/EBITDA | 24.06 |
EPS(TTM)2.06
EY2.33%
EPS(NY)2.53
Fwd EY2.86%
FCF(TTM)2.31
FCFY2.61%
OCF(TTM)2.6
OCFY2.93%
SpS10.36
BVpS16.02
TBVpS11.64
PEG (NY)2.16
PEG (5Y)2.51
Graham Number27.25
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.16% | ||
| ROE | 12.99% | ||
| ROCE | 10.02% | ||
| ROIC | 7.7% | ||
| ROICexc | 18.52% | ||
| ROICexgc | 32.83% | ||
| OM | 23.34% | ||
| PM (TTM) | 20.08% | ||
| GM | 69.11% | ||
| FCFM | 22.3% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexgc growth 3Y-0.4%
ROICexgc growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 3.21 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 63.73% | ||
| Cap/Sales | 2.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.57% | ||
| Profit Quality | 111.05% | ||
| Current Ratio | 13.96 | ||
| Quick Ratio | 11.74 | ||
| Altman-Z | 7.54 |
F-Score5
WACC8.52%
ROIC/WACC0.9
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)23.35%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%15.38%
EPS Next Y19.93%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
EPS Next 5Y9.76%
Revenue 1Y (TTM)14.11%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%15.01%
Revenue Next Year13.86%
Revenue Next 2Y11.2%
Revenue Next 3Y10.46%
Revenue Next 5Y9.67%
EBIT growth 1Y20%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year43.57%
EBIT Next 3Y22.42%
EBIT Next 5YN/A
FCF growth 1Y176.09%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y129.52%
OCF growth 3Y7.93%
OCF growth 5Y25.49%
LEMAITRE VASCULAR INC / LMAT FAQ
What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to LMAT.
Can you provide the valuation status for LEMAITRE VASCULAR INC?
ChartMill assigns a valuation rating of 4 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.
How profitable is LEMAITRE VASCULAR INC (LMAT) stock?
LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 8 / 10.
What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 42.99 and the Price/Book (PB) ratio is 5.53.
What is the expected EPS growth for LEMAITRE VASCULAR INC (LMAT) stock?
The Earnings per Share (EPS) of LEMAITRE VASCULAR INC (LMAT) is expected to grow by 19.93% in the next year.